{
  "docId": "019de070-c935-736b-bfac-0e59550f8f0f",
  "docSlug": "bbdd6d1004c11d68b286eff6aee60dc0",
  "documentTitle": "argenx SE | Results Presentation Deck | 20 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 20,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "The slide compares CR and CRc rates for ITT and patients with >= 2 cycles, while noting 30-day mortality and adverse risk classification.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-c935-736b-bfac-0e59550f8f0f/13",
  "deckHref": "/decks/019de070-c935-736b-bfac-0e59550f8f0f",
  "deckJsonHref": "/decks/019de070-c935-736b-bfac-0e59550f8f0f.json",
  "deckAnchorHref": "/decks/019de070-c935-736b-bfac-0e59550f8f0f#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.15,
        "x": 0.36,
        "y": 0.72
      },
      "kind": "callout",
      "text": "46.2% Adverse Risk Classification (ELN)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5798ce14-7258-4b38-92f1-07ed7e237f14",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.66,
        "y": 0.23
      },
      "kind": "list",
      "text": "Phase 1b ELEVATE Trial in Triple Combination: cusatuzumab + azacitidine + venetoclax",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff76358c-63c5-48e6-8aed-aae173482b32",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.1,
        "y": 0.75
      },
      "kind": "metric",
      "text": "30-day mortality: 5/52 (9.6%)",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "547ed60f-e2a9-40a5-adeb-a1ad3c2088d8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.66,
        "y": 0.63
      },
      "kind": "paragraph",
      "text": "Decision to initiate additional studies will be determined following review of data from ELEVATE",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa657017-7aa2-42c6-9642-db5cf0d021fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.02,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "CRi: Complete Remission with incomplete count recovery; CRh: Complete Remission with partial recovery of peripheral blood counts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16a25baf-4e37-4f80-a9e9-0909462dbc48",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.09,
        "y": 0.42
      },
      "kind": "table",
      "text": "CR Rates table showing ITT and >=2 cycles data for CR and CRc",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "893e0f93-ab58-4ce3-99b1-8e576d9d4443",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.25,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Cusatuzumab Strategy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a921cbf2-05a2-434b-ad78-d14b14a8406a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.05,
        "y": 0.13
      },
      "kind": "title",
      "text": "Newly diagnosed elderly AML patients who are unfit for intensive chemotherapy",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bec8df4f-170f-4fa4-ab18-bd0b0a0508d7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}